Premium
Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?
Author(s) -
Mittal Mayank,
Aggarwal Kul,
Littrell Rachel L.,
Agrawal Harsh,
Alpert Martin A.
Publication year - 2015
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/hdi.12352
Subject(s) - medicine , hemodialysis , pharmacotherapy , intensive care medicine
Cardiovascular disease ( CVD ) occurs commonly in patients with chronic kidney disease ( CKD ) including those treated with hemodialysis ( HD ), and is associated with poor outcomes in this population. Pharmacologic management of hypertension, dyslipidemia, acute and chronic coronary artery disease, and atrial fibrillation in the general population is supported by the results of high‐quality, randomized, controlled clinical trials. Pharmacotherapy of these disorders in the general population is effective in improving clinical outcomes. In contrast, information concerning the effect of pharmacotherapy on mortality and cardiovascular outcomes in patients with CKD , and particularly in HD patients, is limited. Available data suggest that, in general, pharmacotherapy of hypertension and dyslipidemia, anti‐platelet therapy of CVD , and anticoagulant therapy in patients with atrial fibrillation are less effective in HD patients than in the general population or even in patients with early stage of CKD .